Apexigen, Inc. Common Stock
APGN
APGN was delisted on the 22nd of August, 2023.
0 hedge funds and large institutions have $0 invested in Apexigen, Inc. Common Stock in 2023 Q3 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 0 reducing their positions, and 17 closing their positions.
100% less funds holding
Funds holding: 17 → 0 (-17)
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
100% less capital invested
Capital invested by funds: $1.37M → $0 (-$1.37M)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 17
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DCMIC
Decheng Capital Management III (Cayman)
Grand Cayman,
Cayman Islands
|
-$814K |
| 2 |
YF
Yu Fan
|
-$173K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
-$110K |
| 4 |
BlackRock
New York
|
-$91.9K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
-$76.8K |
APGN Hedge Fund Activity: Q3 2023 in Review
0 of the 6,301 institutional investors tracked by Wall St. Rank reported a position in Apexigen, Inc. Common Stock (APGN) for Q3 2023, worth a combined $0 — down 100% from $1.37M a quarter earlier.
Sellers outnumbered buyers: 17 funds closed out of APGN and 0 opened new positions — a net loss of 17 holders — while 0 trimmed existing stakes and 0 added.
The largest seller was Decheng Capital Management III (Cayman), exiting entirely with an estimated $814K sold.
- 0 institutional investors held Apexigen, Inc. Common Stock (APGN) as of Q3 2023, down from 17 in Q2 2023.
- Funds reported $0 of Apexigen, Inc. Common Stock stock for Q3 2023, down 100% quarter-over-quarter.
- 0 funds opened new Apexigen, Inc. Common Stock positions in Q3 2023 and 17 closed out, a net change of -17 holders.
- The largest Apexigen, Inc. Common Stock seller in Q3 2023 was Decheng Capital Management III (Cayman), an estimated $814K sold.
Based on aggregated 13F filings for Q3 2023.